DuoHexaBody-CD37(®), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies

Tetraspanin CD37 has recently received renewed interest as a therapeutic target for B-cell malignancies. Although complement-dependent cytotoxicity (CDC) is a powerful Fc-mediated effector function for killing hematological cancer cells, CD37-specific antibodies are generally poor inducers of CDC. T...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Cancer J
Auteurs principaux: Oostindie, Simone C., van der Horst, Hilma J., Kil, Laurens P., Strumane, Kristin, Overdijk, Marije B., van den Brink, Edward N., van den Brakel, Jeroen H. N., Rademaker, Hendrik J., van Kessel, Berris, van den Noort, Juliette, Chamuleau, Martine E. D., Mutis, Tuna, Lindorfer, Margaret A., Taylor, Ronald P., Schuurman, Janine, Parren, Paul W. H. I., Beurskens, Frank J., Breij, Esther C. W.
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7186228/
https://ncbi.nlm.nih.gov/pubmed/32341336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-0292-7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires